Daiichi Sankyo Company has opened the Orphan Disease Treatment Institute office inside the Daiichi Sankyo Shinagawa R&D center.
Innovation Network Corporation of Japan, a fund managed by Mitsubishi UFJ Capital, and Daiichi Sankyo have jointly invested in the Orphan Disease Treatment Institute.
With the opening of the new office, the company expects to completely focus on the development activities of Duchenne muscular dystrophy therapy (DMD).
DMD is associated with muscular atrophy which progresses with age, causing various impairments to mobility and finally resulting in death for many in their 20s and 30s.
Source:
http://drugdiscovery.pharmaceutical-business-review.com/news/daiichi-sankyo-opens-office-of-orphan-disease-treatment-institute-010413